Browsed by
Month: April 2011

Topoisomerase I Not Simply Adjusting Genome Topology

Topoisomerase I Not Simply Adjusting Genome Topology

Topoisomerases are well known to be essential for all aspects of DNA function, from replication to repair and particularly in transcription. For this reason, they have for many years been excellent DNA damaging agents that display selectively for tumor cells. A relatively recent finding has come to light that involves topoisomerase I and induction of cellular senescence. Cellular senescence is a form of tumor suppression that puts cells in a more or less permanent proliferative arrest. It is induced by…

Read More Read More

Upcoming Closure May 4-18

Upcoming Closure May 4-18

Our business and shipping facilities will be closed May 4-18 while our staff visits with collaborators in Europe. During this time we will be answering voicemails and emails, so please do continue to contact us. Our offices will be resume our normal product shipping regimen on May 23. Thank you!

Rapid Transport of Novel Topo II Inhibitor into Cancer Cells

Rapid Transport of Novel Topo II Inhibitor into Cancer Cells

F14512, a Potent Antitumor Agent Targeting Topoisomerase II Vectored into Cancer Cells via the Polyamine Transport System Jean-Marc Barret, Anna Kruczynski, StĂ©phane VispĂ©, et al. Abstract The polyamine transport system (PTS) is an energy-dependent machinery frequently overactivated in cancer cells with a high demand for polyamines. We have exploited the PTS to selectively deliver a polyamine-containing drug to cancer cells. F14512 combines an epipodophyllotoxin core-targeting topoisomerase II with a spermine moiety introduced as a cell delivery vector. The polyamine tail…

Read More Read More

Doxorubicin: A Preclinical Study

Doxorubicin: A Preclinical Study

Sequencing of Type I Insulin-Like Growth Factor Receptor Inhibition Affects Chemotherapy Response In vitro and In vivo Xianke Zeng,1,2 Deepali Sachdev,2 Hua Zhang,2 Martine Gaillard-Kelly,3 and DouglasYee1,2 Abstract Purpose: The aim of this study was to determine the optimal sequence of combining anti-type I insulin-like growth factor receptor (IGF1R) antibodies with chemotherapeutic drugs in cancer cells in vitro and in vivo. Experimental Design: MCF-7 and LCC6 cells were treated with subcytotoxic concentrations of doxorubicin with or without anti-IGF1R antibodies (scFv-Fc…

Read More Read More